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Abstract
Although statins decrease cholesterol synthesis, they also possess ‘pleiotropic’ effects, such as
enhancing the function of vascular endothelium and the stability of atherosclerotic plaques.
Furthermore, they attenuate oxidative stress, inflammation, and the prothrombotic response. These
diverse biological actions may explain their perioperative protective effects, especially in patients
undergoing cardiac and major vascular procedures. Beyond reductions in perioperative mortality and
cardiorenal complications, recent evidence also suggests outcome benefits from statin exposure in
sepsis, airway hyperreactivity, and venous thromboembolism. It is likely that these agents will be
increasingly prescribed perioperatively as high-quality evidence from well-designed randomized trials
becomes available in the near future.
Introduction and context
Given that about 230 million surgeries are performed
worldwideeachyear,the impact ofperioperative outcome
benefits from statins is important [1,2]. Cardiac complica-
tions remain the most common cause of perioperative
mortality and major morbidity [3,4]. Perioperative myo-
cardial infarction (PMI) has two major identifiedmechan-
isms:thefirstiscoronaryplaqueinstabilityandthesecond
is oxygen supply/demand mismatch from perioperative
stressors such as tachycardia, hypertension, and pain [5].
Recent evidence suggests that statins may protect against
PMIbystabilizingcoronaryplaquestopreventsubsequent
rupture and coronarythrombosis [4-6].Recent statin trials
have focused on extending this perioperative ischemic
benefit by investigating optimal therapy, appropriate
patient populations, and high-risk surgical procedures.
Furthermore, pleiotropic properties of statins, such as
suppression of inflammation, immunomodulation, and
protection against thrombosis, are being explored for
perioperative benefit.
Recent advances
Recent meta-analysis has generated strong evidence that
statins improve outcomes after cardiac surgery. In a large
meta-analysis (n = 31,725), preoperative statin exposure
significantly reduced early mortality (odds ratio [OR]
0.57; 95% confidence interval [CI] 0.49-0.67), stroke
(OR 0.74; 95% CI 0.60-0.91) and atrial fibrillation (OR
0.67; 95% CI 0.51-0.88) [7]. In a follow-up meta-
analysis focused on atrial fibrillation (n = 17,643), these
investigators demonstrated in pooled analysis of both
randomized and observational trials that preoperative
statin exposure significantly protected against new-onset
atrial fibrillation after cardiac surgery (OR 0.66; 95% CI
0.48-0.89) [8]. These protective effects of statins against
atrial fibrillation after cardiac surgery were again
confirmed in two independent meta-analyses [9,10]. In
summary, the first analysis (n = 7041) yielded a relative
ratio of 0.61 (95% CI 0.49-0.76) and the second
(n = 3557) an OR of 0.39 (95% CI 0.18-0.85) [9,10].
Furthermore, perioperative statin exposure has also
been demonstrated in observational trials to be nephro-
protective [11-13]. A retrospective analysis (n = 1802;
coronary artery bypass grafting from 2002 to 2005)
demonstrated in multivariate analysis that preoperative
statin exposure significantly reduced the risk of
postoperative renal insufficiency (OR 0.54; 95% CI
0.30-0.99; P = 0.047) [13]. Recent evidence also strongly
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even when started after cardiac surgery [14-16]. These
strongly suggestive data sets are consistent across multi-
ple meta-analyses and therefore explain the rationale for
the multiple randomized clinical trials in adult cardiac
surgery that are currently in progress to confirm the safety
and efficacy of perioperative statin therapy (full details
available at ClinicalTrials.gov [17]).
Recenttrialshavealsoprovidedstrongevidencethatstatins
improve outcome after noncardiac surgery. The disconti-
nuation of long-term statin therapy after major vascular
surgery significantly increases perioperative cardiac risk
[18,19].Inanobservationaltrial(n = 298),interruptionof
long-term statin therapy after major vascular surgery
significantly increased postoperative troponin release
(hazard ratio [HR] 4.6; 95% CI 2.2-9.6) as well as PMI
and cardiovascular death (HR 7.5; 95% CI 2.8-20.1) [19].
Furthermore, short-term perioperative statin therapy
(n = 497) in major vascular surgery significantly decreased
postoperative myocardial ischemia (10.8% versus 19.0%;
HR 0.55; 95% CI 0.34-0.88; P = 0.01) and death (4.8%
versus 10.1%; HR 0.47; 95% CI 0.24-0.94; P = 0.03) [20].
Even single-dose statin therapy merits further attention
perioperatively,given thatit significantly reduces PMIafter
elective percutaneous coronary intervention (9.5% versus
15.8%; OR 0.56; 95% CI 0.35-0.89; P = 0.014) [21].
Although the cardiovascular protective effects of perio-
perative statins might apply to intermediate-risk patients
undergoing noncardiovascular surgery, further trials are
required for conclusive evidence [22].
Besides cardiovascular protection, statin exposure offers
the possibility of widespread therapeutic potential
throughout perioperative medicine. A large observa-
tional trial (n = 2170; vascular surgery from 1995 to
2006) demonstrated that, in multivariate analysis, statin
exposure significantly improved the incidence of com-
plete renal recovery (OR 2.0; 95% CI 1.0-3.8) [23]. The
pleiotropic effects of statins also have emerging ther-
apeutic applications in sepsis, attenuation of bronchial
hyperreactivity, and prevention of venous thrombosis
[24-27]. The significant perioperative outcome benefits
due to statin exposure have led to a proliferation of
randomized trials exploring their therapeutic potential
and safety throughout adult noncardiac perioperative
practice (full details available at ClinicalTrials.gov [17]).
Implications for clinical practice
Based on recent evidence, the pleiotropic effects of statins
have significant therapeutic potential throughout peri-
operative medicine both in cardiac and noncardiac
practice. Further trials are required to develop a rational,
safe, and comprehensive strategy for perioperative risk
reduction with these agents.
There is strong evidence that statin therapy for patients
undergoing cardiovascular procedures, whether pre-
existing or newly started, significantly reduces adverse
cardiac outcomes, including mortality. As a result, statin
therapy is already strongly recommended for these
patient groups in recent perioperative guidelines [4].
Given the explosion of statin randomized trials through-
out perioperative medicine, it is likely that the perio-
perative indications for these remarkable agents will be
significantly extended based on the latest trials. There is a
clinical priority for an intravenous statin formulation to
ensure continuous statin exposure throughout the
perioperative period to maximize their clinical benefit.
It is reasonable to choose a long-acting statin such as
extended release fluvastatin (80 mg/day) in the pre-
operative period to extend its beneficial effects into the
postoperative period [20,28]. Thereafter, the statin
should be continued as soon as possible postoperatively
to maximize its perioperative benefit [4,28]. Although
the perioperative safety of statins has been established in
large trials, their well-known side-effects of myositis,
rhabdomyolysis, and liver toxicity should be kept in
mind. In patients exposed to perioperative statins,
symptoms and signs of myositis (muscle cramps,
myalgias) and/or liver toxicity (jaundice, hepatic tender-
ness) should prompt serum testing for creatine kinase
levels and/or liver function tests, including aminotrans-
ferase levels [28]. Rhabdomyolysis can also present as an
unexplained deterioration in renal function, which can
progress to renal failure. Furthermore, the risk of
rhabdomyolysis is more common when a statin is
combined with fibrate therapy for more aggressive
control of dyslipidemia [29]. In summary, if any of
these syndromes develop, the statin should be immedi-
ately discontinued and full supportive care initiated.
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